PINK1 Q456X

PINK1 (PTEN-induced kinase 1) serves as a critical guardian of mitochondrial health by detecting damaged mitochondria and recruiting repair machinery through a process called mitophagy—the selective removal of defective cellular power plants. When mitochondria become damaged, PINK1 accumulates on their outer membrane and activates another protein called Parkin, which tags the mitochondria for destruction. Mutations in PINK1 account for up to 9% of early-onset Parkinson's disease cases in certain geographic regions, with approximately 90% of disease-causing mutations clustering in the protein's kinase domain—the enzymatic region responsible for phosphorylating target proteins [1]. Understanding the wild-type structure provides the baseline needed to interpret how over 100 documented mutations across the protein's different domains lead to neurodegeneration [4]. This AlphaFold2 structure prediction achieved an average confidence score (pLDDT) of 72.2, indicating moderate overall reliability. Regions with scores above 70 are generally considered trustworthy for identifying secondary structure elements and domain architecture, while lower-confidence regions require careful interpretation and should not be used for detailed atomic-level conclusions without experimental validation. The confidence level suggests that while the overall fold is likely reasonable, specific structural details—particularly in flexible or disordered regions—remain uncertain and would benefit from experimental techniques like X-ray crystallography or cryo-electron microscopy to validate. PINK1 contains several functionally critical regions that are targets of disease mutations. The transmembrane region anchors the protein to mitochondrial membranes, and mutations here such as R98W alter how the protein inserts into membranes, causing inappropriate removal of healthy mitochondria and impaired recruitment of Parkin—all without major defects in how the protein is cleaved by another enzyme called PARL [4]. The kinase domain, where most pathogenic mutations occur, becomes destabilized by variants like Glu240Lys, Gly309Asp, and Leu489Pro, which impair the protein's ability to bind ATP (its energy source) and phosphorylate targets, ultimately disrupting the entire mitophagy quality control system [1]. These structural disruptions lead to accumulation of damaged mitochondria that produce harmful reactive oxygen species and release mitochondrial DNA into the cell, triggering inflammatory responses through the cGAS-STING pathway [2]. The clinical significance of PINK1 mutations extends beyond simple loss of mitophagy function. Recent genetic studies have identified novel variants across diverse populations, including a homozygous PINK1 variant in Cretan patients, highlighting the importance of population-specific genetic screening [4]. Current genetic testing recommendations prioritize young-onset patients and those with family history, though there is ongoing debate about optimal screening strategies [3]. Importantly, the PINK1/Parkin pathway has emerged as a promising therapeutic target, with small molecule activators showing potential to lower the threshold for mitophagy activation and rescue function even in the presence of some mutations [1]. Understanding the wild-type structure at atomic resolution remains essential for rational drug design aimed at stabilizing mutant proteins or enhancing their residual activity, potentially offering disease-modifying treatments for the substantial subset of Parkinson's patients carrying PINK1 mutations.